28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Many studies have explored whether individual plasma protein biomarkers improve cardiovascular disease risk prediction. 4 key findings →
Participants: 4,857 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Portable, low‐field imaging could be useful for identifying moderate to severe WMHs. 4 key findings →
Design: prospective cohort Participants: 33 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Disturbing dreams were reported by 24.2% overall and all-cause dementia, and AD incidence was 10.8 and 5.3 per 1000 person-years, respectively. 5 key findings →
Design: cohort study Participants: 10,238 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 8870 cases of all-cause dementia were observed over a median 13.9-year follow-up. 5 key findings →
Design: cohort study Participants: 782 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 9,361 randomized participants, 7,221 (77%) were eligible to be re-contacted. 5 key findings →
Participants: 248 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 5 721 711 patients (3 302 579 female and 2 419 132 male) with incident dementia between 2014 and 2021 were included in the study. 5 key findings →
Design: cohort study Participants: 711 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 736 patients (245 [33%] female, mean age 68·0 years [SD 11·2], median admission National Institutes of Health Stroke Scale (NIHSS) 3 [IQR 1-5]), 557 (76%) were followed up until death or the end of the study, and 706 (96%) contributed to the PSD analysis. 5 key findings →
Design: prospective cohort Participants: 736 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study included 1526 early adult-life (mean [SD] age, 36.7 [4.7] years; 821 [53.8%] female), 1943 midlife (mean [SD] age, 54.0 [5.8] years; 1010 [52.0%] female), and 885 late-life (mean [SD] age, 71.0 [4.5] years; 473 [53.4%] female) participants. 5 key findings →
Design: cohort study Participants: 1,526 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 14 participants (2 in part A and 12 in parts B and C) completed at least 12 months of follow-up and were included in the analyses. 5 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among 13 592 participants (mean [SD] age, 58.34 [9.39] years; 7175 [52.8%] female), 6525 (48.0%) experienced possible childhood loneliness, and 565 (4.2%) reported childhood loneliness. 5 key findings →
Design: cohort study Participants: 592 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Air pollution is one of the most serious environmental problems that afflict our planet and one of the greatest risk factors for human health. 3 key findings →
Design: systematic review Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity. 4 key findings →
Participants: 215,970 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In the present study, higher adherence to MeDi was associated with a reduced risk for dementia and cognitive decline in a traditional Mediterranean population. 5 key findings →
Design: longitudinal study Participants: 62 Evidence: moderate
Full summary, score breakdown and related studies → Original source
MET-FINGER aims to test a FINGER 2.0 multimodal intervention, combining an updated FINGER multidomain lifestyle intervention with metformin, where appropriate, in an APOE ε4-enriched population of older adults (60-79 years) at increased risk of dementia. 2 key findings →
Participants: 600 Evidence: high
Full summary, score breakdown and related studies → Original source
Greater adherence to hPDI, MDS, RFS, and MIND was individually associated with larger brain volumes in specific regions. 5 key findings →
Design: cross-sectional Participants: 114,684 Evidence: low
Full summary, score breakdown and related studies → Original source
Subclinical structural brain abnormalities in high-functioning older adults can increase the risk of developing physical disabilities and declining in motor performance. 1 key finding →
Design: longitudinal study Participants: 2,450 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Patients with AD have altered microvascular network in the retina (narrower retinal venules and a sparser and more tortuous retinal vessels) compared with matched nondemented controls. 3 key findings →
Design: case-control study Participants: 136 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In the general population, the use of statins, but not of non-statin cholesterol-lowering drugs, was associated with a lower risk of AD compared with never use of cholesterol-lowering drugs. 5 key findings →
Design: cross-sectional Participants: 6,992 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this cohort study, statin therapy was not associated with a decreased risk of dementia. 5 key findings →
Design: cohort study Participants: 2,798 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this population-based longitudinal study, carotid IMT was associated with a higher risk of developing cognitive impairment during the 10-year follow-up, and was associated with poorer performance in a test of executive function 10 years later. 5 key findings →
Design: longitudinal study Participants: 1,651 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In cognitively unimpaired adults with increased risk for AD, increased exposure to air pollution was suggested to be associated with greater global atrophy and reduced volume and thickness in specific brain areas known to be affected in AD, thus suggesting a potential link between environmental exposures and cerebral vulnerability to AD. 4 key findings →
Design: prospective cohort Participants: 958 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our results showed a positive association between exposure to NOx and O 3 and hospitalization for dementia and a negative association between NO 2 exposure and hospitalization for dementia. 5 key findings →
Participants: 350,844 Evidence: moderate
Full summary, score breakdown and related studies → Original source
To review the evidence for risk factors of Creutzfeldt-Jakob disease (CJD), we pooled and reanalyzed the raw data of three case-control studies. 4 key findings →
Design: case-control study Participants: 178 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our results support an association between anemia experienced early in life and the later development of Parkinson disease. 5 key findings →
Design: case-control study Participants: 196 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study demonstrates that influenza vaccination is associated with reduced AD risk in a nationwide sample of US adults aged 65 and older. 2 key findings →
Participants: 2,356,479 Evidence: moderate
Full summary, score breakdown and related studies → Original source
10 of the 3,281 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →